18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study

  • Luka LezaicEmail author
  • Sebastijan Rep
  • Mojca Jensterle Sever
  • Tomaz Kocjan
  • Marko Hocevar
  • Jure Fettich
Original Article



Primary hyperparathyroidism is a common endocrine disorder which is diagnosed biochemically and for which therapy is surgical. A prerequisite for minimally invasive surgery, which minimizes morbidity and cost, is accurate localization of the involved gland(s). The aim of this study was to evaluate the usefulness of 18F-fluorocholine PET/CT for preoperative localization of hyperfunctioning parathyroid tissue.


18F-Fluorocholine PET/CT and conventional parathyroid scintigraphic imaging consisting of 99mTc-sestaMIBI SPECT/CT, 99mTc-sestaMIBI dual-phase imaging and 99mTc-sestaMIBI/pertechnetate subtraction imaging were performed in 24 patients. The diagnostic performance of the imaging methods was compared against histology as the gold standard and postoperative serum Ca2+ and iPTH values.


The sensitivity and specificity of 18F-fluorocholine PET/CT were 92 % and 100 %, respectively, in contrast to 49 % and 100 %, 46 % and 100 %, and 44 % and 100 % for 99mTc-sestaMIBI SPECT/CT, 99mTc-sestaMIBI/pertechnetate subtraction imaging and 99mTc-sestaMIBI dual-phase imaging, respectively. Combined conventional scintigraphic imaging had a sensitivity and specificity of 64 % and 100 %, respectively. The performance of 18F-fluorocholine PET/CT was superior particularly in patients with multiple lesions or hyperplasia.


18F-Fluorocholine PET/CT appears to be a promising, effective imaging method for localization of hyperfunctioning parathyroid tissue.


18F-Fluorocholine Hyperparathyroidism PET/CT 


Conflicts of interest



  1. 1.
    Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg Clin N Am. 2009;89:1205–25.PubMedCrossRefGoogle Scholar
  2. 2.
    Johnson NA, Carty SE, Tublin ME. Parathyroid imaging. Radiol Clin N Am. 2011;49:489–509.PubMedCrossRefGoogle Scholar
  3. 3.
    Taieb D, Hindie E, Grassetto G, Colletti PM, Rubello D. Parathyroid scintigraphy: when, how, and why? A concise systematic review. Clin Nucl Med. 2012;37(6):568–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Grassetto G, Alavi A, Rubello D. PET and parathyroid. PET Clin. 2008;2:385–93.CrossRefGoogle Scholar
  5. 5.
    Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med. 2012;26:451–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011;52:81–9.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Ishizuka T, Kajita K, Kamikubo K, Komaki T, Miura K, Nagao S, et al. Phospholipid/Ca2+-dependent protein kinase activity in human parathyroid adenoma. Endocrinol Jpn. 1987;34:965–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Neumann DR, Esselstyn Jr CB, MacIntyre WJ, Chen EQ, Go RT, Kohse LM, et al. Primary hyperparathyroidism: preoperative parathyroid imaging with regional body FDG PET. Radiology. 1994;192:509–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Neumann DR, Esselstyn CB, Maclntyre WJ, Go RT, Obuchowski NA, Chen EQ, et al. Comparison of FDG-PET and sestamibi-SPECT in primary hyperparathyroidism. J Nucl Med. 1996;37:1809–15.PubMedGoogle Scholar
  10. 10.
    Sisson JC, Thompson NW, Ackerman RJ, Wahl RL. Use of 2-[F-18]-fluoro-2-deoxy-D-glucose PET to locate parathyroid adenomas in primary hyperparathyroidism. Radiology. 1994;192:280.PubMedCrossRefGoogle Scholar
  11. 11.
    Melon P, Luxen A, Hamoir E, Meurisse M. Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Eur J Nucl Med. 1995;22:556–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Herrmann K, Takei T, Kanegae K, Shiga T, Buck AK, Altomonte J, et al. Clinical value and limitations of [11C]-methionine PET for detection and localization of suspected parathyroid adenomas. Mol Imaging Biol. 2009;11:356–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Tang BN, Moreno-Reyes R, Blocklet D, Corvilain B, Cappello M, Delpierre I, et al. Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging. 2008;3:157–63.PubMedCrossRefGoogle Scholar
  14. 14.
    Lange-Nolde A, Zajic T, Slawik M, Brink I, Reincke M, Moser E, et al. PET with 18F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism. A pilot study. Nuklearmedizin. 2006;45:193–6.PubMedGoogle Scholar
  15. 15.
    Hindié E, Ugur O, Fuster D, O’Doherty M, Grassetto G, Ureña P, et al. 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging. 2009;36:1201–16.PubMedCrossRefGoogle Scholar
  16. 16.
    Nichols KJ, Tomas MB, Tronco GG, Rini JN, Kunjummen BD, Heller KS, et al. Preoperative parathyroid scintigraphic lesion localization: accuracy of various types of readings. Radiology. 2008;248:221–32.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Luka Lezaic
    • 1
    Email author
  • Sebastijan Rep
    • 1
  • Mojca Jensterle Sever
    • 2
  • Tomaz Kocjan
    • 2
  • Marko Hocevar
    • 3
  • Jure Fettich
    • 1
  1. 1.Department for Nuclear MedicineUniversity Medical Centre LjubljanaLjubljanaSlovenia
  2. 2.Department of Endocrinology, Diabetes and Metabolic DiseasesUniversity Medical Centre LjubljanaLjubljanaSlovenia
  3. 3.Department of Surgical OncologyInstitute of OncologyLjubljanaSlovenia

Personalised recommendations